Ladekarl, M 2023, ' Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit? ', Chinese clinical oncology, vol. 12, no. 2, 10, pp. 10 . https://doi.org/10.21037/cco-23-17
Vesteghem, C, Dahl, S C, Brøndum, R F, Sønderkær, M, Bødker, J S, Schmitz, A, Weischenfeldt, J, Pedersen, I S, Sommer, M, Rytter, A S, Nielsen, M M, Ladekarl, M, Severinsen, M T, Dybkær, K, Grønbæk, K, El-Galaly, T, Roug, A S & Bøgsted, M 2022 ' Implementing a data infrastructure for precision oncology projects leveraging REDCap ' medRxiv, medRxiv . https://doi.org/10.1101/2022.05.09.22274599